Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sintilimab Plus Chemotherapy in EGFR-mutant NSCLC
NCT05244213Phase 2Active, not recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Major Pathological Response. Started Jun 2022; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05244213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05244213.